Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has finalized a $210 million deal to sell a Rare Pediatric Disease Priority Review Voucher (PRV). The voucher was awarded following the FDA approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), the first treatment targeting the underlying cause of glycogen storage disease type Ia (GSDIa).